ProCE Banner Activity

Phase III KEYNOTE-204: Pembrolizumab vs Brentuximab Vedotin in Relapsed/Refractory Classical Hodgkin Lymphoma

Slideset Download
Conference Coverage
Pembrolizumab significantly improved PFS in patients with relapsed/refractory cHL vs brentuximab vedotin, including those ineligible for ASCT, with primary refractory disease, and who were brentuximab vedotin naive.

Released: June 09, 2020

Expiration: June 08, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono